Xenon Pharmaceuticals Inc. - 8-K Filing
Xenon Pharmaceuticals reports Q3 2026 results with $1.2B cash runway into 2029 and FDA NDA submission for azetukalner in focal seizures. (Items: 2.02 Results of Operations and Financial Condition On November 9, 2026, Xenon Pharmaceuticals Inc, 7.01 Regulation FD Disclosure The Company announces material information to the public through a variety of means, including filings with the Secu, 9.01 Financial Statements and Exhibits (d) Exhibits)
Tickers: $XENE
Read the full article at SEC EDGAR
Part of the story IDEAYA Biosciences, Inc. - 8-K Filing (42 articles)